Treatment Centres

For HCPs / Treatment Centres

CHEMOSAT is currently available in over 22 centres throughout Europe.

In order to seek treatment a patient will need to be referred their treating medical oncologist.

Download Referral Form

Institut für Diagnostische und Interventionelle Radiologie
Prof. Dr. med. Frank Wacker,
Carl-Neuberg-Straße 1,
30625 Hannover
Germany

Tel +49 511 532 3421
radiologie@mh-hannover.de
Visit Website →

Hautklinik und Universitätsklinik Heidelberg
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT)
Prof. Dr. med. Jessica Hassel,
Tel +49 6211 568562
NCT.DermaOnko@med.uni-heidelberg.de

Prof. Dr. med. Mark Oliver Wielpütz,
Interventional Radiology,
interventionsmanagement.radia@med.uni-heidelberg.de

Hauttumorzentrum,
Im Neuenheimer Feld 460

Visit Website →

Universitätsklinikum Würzburg
Univ.-Prof. Dr. med. Ralph Kickuth,
Institut für Diagnostische und Interventionelle Radiologie,
Oberdürrbacher Straße 6,
97080 Würzburg
Germany

Tel +49 931 201 34957
kickuth_r@ukw.de
Visit Website →

Universitätsklinikum Tübingen
Prof. Dr. med. Gerd Grözinger,
Diagnostische und Interventionelle Radiologie,
Hoppe-Seyler Straße 3,
72076 Tübingen
Germany

Tel +49 707 129 82087
gerd.groezinger@med.uni-tuebingen.de
Visit Website →

Asklepios Klinik Barmbek
Prof. Dr. med. Roland Brüning,
Radiologie und Neuroradiologie,
Rübenkamp 220,
22291 Hamburg
Germany

Tel +49 181 882 9811
roentgen.barmbek@asklepios.com
Visit Website →

Katholische Marienkrankenhaus gGmbH
Herr Prof. Dr. med. Christian R. Habermann,
Institut für Diagnostische und Interventionelle Radiologie,
Alfredstraße 9,
22087 Hamburg
Germany

Tel +49 402 546 1774
intervention.radiologie@marienkrankenhaus.org
Visit Website →

Universitätsklinikum Leipzig
Dr. med. Sebastian Ebel,
Klinik und Poliklinik für Diagnostische und Interventionelle,
Ambulanz für Minimal-Invasive Diagnostik und Therapie (AMIT),
Liebigstr. 20, Haus 4,
04299 Leipzig
Germany

Tel +49 341 971 7100
amit@medizin.uni-leipzig.de
Visit Website →

Universitätsklinikum Giessen und Marburg
Univ.-Prof. Dr. med. Andreas H. Mahnken,
Klinik für Diagnostische und Interventionelle Radiologie,
Baldingerstrasse,
35043 Marburg
Germany

radiologie@med.uni-marburg.de

Comprehensive Cancer Center Marburg
Dr. Martin Gschnell,
Hauttumorzentrum,
Klinik für Dermatologie und Allergologie UKGM Marburg,
Baldingerstraße
35043 Marburg
Germany

Tel +49 6421 58 69115
martin.gschnell@med.uni-marburg.de
Visit Website →

Charité – Universitätsmedizin Berlin
PD Dr. med. Dr. rer. oec. Maximilian de Bucourt,
Interventional Radiology,
maximilian.de-bucourt@charite.de

Dr. med. Caroline Anna Peuker,
Internal Oncology,
caroline-anna.peuker@charite.de

Campus Benjamin Franklin,
Klinik für Radiologie,
Hindenburgdamm 30,
12203 Berlin

University Hospital Southampton NHS Foundation Trust
Dr. Brian Stedman, Consultant Interventional Oncologist,
Dr. Sachin Modi, Consultant Interventional Radiologist,
Department of Interventional Radiology,
Tremona Road,
Southampton SO16 6YD,
United Kingdom

Tel +44 238 120 3492
Jayne.Pointer@uhs.nhs.uk

Spire Hospital Southampton
Ms. Debbie Brooks,
Patient Coordinator,
Chalybeate Close,
Southampton,
Hampshire SO16 6UY,
United Kingdom

Tel +44 238 076 4352
debbie.brooks@spirehealthcare.com
Visit Website →

The Harley Street Clinic
Dr Julian Hague / Dr George (Jowad) Raja / Dr Graham Munneke
Interventional Radiologist
35 Weymouth Street
Marylebone
London W1G 8BJ
United Kingdom

Tel +44 207 908 3756
info@lion-oncology.com
Visit Website →

The Christie Hospital
The Christie Private Care
Dr Greg Wilson
Consultant Medical Oncologist
Wilmslow Road,
Manchester
M20 4BX
United Kingdom

Tel +44 161 918 7539
Alison.Mitchell20@nhs.net

Leiden University Medical Centre (LUMC)
Dr Ellen Kapiteijn
Medical Oncologist
Albinusdreef 2
2333ZA Leiden
The Netherlands

Tel+31 71 526 9111
h.w.kapiteijn@lumc.nl
m.c.burgmans@lumc.nl

Istituto Europeo di Oncologia
Dr. Franco Orsi,
Medical Director, Unit of Interventional Radiology,
Via Ripamonti 435,
20141 Milan,
Italy

Tel+39 (0)02 57489060
franco.orsi@ieo.it

In Turkey, Delcath is represented through a distributor partner - Boyd Medical.

Boyd Medical Turkey Tibbi̇ Ürünler Ti̇caret Anoni̇m Şi̇rketi̇
Konutkent Mah. 3035. Cad. No:74 Suit Tower,
A Blok D. 87 Çankaya 06810 Ankara,
Turkey

Tel+90 312 217 22 36
Tel+90 539 437 80 83
info@boydmedical.nl

Prof. Dr. Çağatay Arslan,
Medical Oncologist,
İEU Medical Point İzmir Hospital
cagatay.arslan@mph.com.tr

Asst. Prof. Dr. Utku Mahir Yildirim,
Interventional Radiologist,
İEU Medical Point İzmir Hospital
utkumahir.yildirim@mph.com.tr
Tel+90 506 626 62 10

Salgrenska University Hospital
Prof. Roger Olofsson Bagge,
Surgical Oncologist,
Blå stråket 5,
413 45 Göteborg,
Sweden

Tel+4670-7462119
Roger.olofsson.bagge@gu.se

A medical oncologist will usually be responsible for ensuring that CHEMOSAT is the right treatment approach for their patient. They are experienced in the monitoring of toxicities of chemotherapy and are responsible for the complete medical management of the patient, including, but not limited to, pre- and postoperative care. They may also be responsible for monitoring the patient during the immediate post-procedure period.

A qualified intensivist, or appropriately qualified critical care specialist, is responsible for providing medical management of the patient in the immediate post-procedure period, during which the patient is in the intensive care unit or step down unit.

A qualified interventional radiologist with the knowledge, skills, experience, and hospital privileges required to perform advanced vascular interventional procedures.

A qualified chemotherapy healthcare professional certified by the site to deliver chemotherapy, such as Interventional Radiology Technician or Registered Nurse.

A qualified perfusionist is required to establish, monitor, and control the extracorporeal pump and veno-venous bypass circuit.

A qualified anaesthetist (anaesthesiologist) and/or nurse anaesthetist responsible for the management of sedation, analgesia, respiratory and cardiovascular support.

A qualified pharmacist, on call during the procedure, to reconstitute the chemotherapeutic agent (melphalan hydrochloride), using national and local safety guidelines. The pharmacist should be aware of the rapid preparation time required for the preparation and administration of melphalan for use with CHEMOSAT.

Male or female patient > 18 years of age with a life expectancy of at least 3 months
Weight > 35kg
Surgically unresectable primary or metastatic cancer of the liver*
Must have recovered from all side effects of prior therapeutic and diagnostic interventions
ECOG performance status of 0 to 1 at screening and on the day prior to each treatment
Adequate hepatic, haematologic and renal function
Cardiac and anaesthetic clearance before the procedure
Negative serum pregnancy test, if applicable

*Patients with 50% or greater tumour burden of the liver on imaging should have a laparoscopy and normal liver biopsied for both visual inspection of liver parenchyma and histological examination of the liver to rule out hepatocellular dysfunction at a subclinical level

Screens and refers patients in consultation with MDT to referral site.
Drafts referral letter, completes the referral form and sends to CHEMOSAT Expert Centre.

Patient referral form
Reviews imaging in consultation with MDT
The following tests must have been completed and sent to the CHEMOSAT Expert site:

MRI brain
CT chest/pelvis
CT or MRI abdomen
MRA of abdomen
Diagnostic laporscopy (if indicated)
Endoscopy (if indicated)
PET/CT

Week 1 - blood tests

Week 2 - blood tests

Week 3 - blood tests

Week 6-8 - post treatment MRI to assess response

The following pages are exclusively reserved for health care professionals licensed in the European Union, the United Kingdom, Switzerland, Norway, Iceland, Turkey & Liechtenstein where the product has been CE marked.

If you are located outside of these regions, please click here (www.delcath.com)

Information provided on this site is not intended to be professional medical advice. Product Instructions for Use (IFU) should be consulted before use of the product.

I UNDERSTAND AND AGREE TO THE STATEMENT ABOVE

Publication Date	Document and Revision number	Language
26-JUL-2023	120056 Rev E	English • Download
21-APR-2022	120056 Rev D	English • Download
08-MAR-2021	120056 Rev C	English • Download

Publication Date	Document and Revision number	Language
26-JUL-2023	120056 Rev E	Czech • Download
26-JUL-2023	120056 Rev E	English • Download
21-APR-2022	120056 Rev D	Czech • Download
21-APR-2022	120056 Rev D	English • Download
08-MAR-2021	120056 Rev C	Czech • Download
08-MAR-2021	120056 Rev C	English • Download

Publication Date	Document and Revision number	Language
22-JAN-2024	120057 Rev F	French • Download
22-JAN-2024	120057 Rev F	English • Download
26-JUL-2023	120057 Rev E	French • Download
26-JUL-2023	120057 Rev E	English • Download
21-APR-2022	120057 Rev D	French • Download
21-APR-2022	120057 Rev D	English • Download
08-MAR-2021	120057 Rev C	French • Download
08-MAR-2021	120057 Rev C	English • Download

Publication Date	Document and Revision number	Language
26-JUL-2023	120055 Rev F	German • Download
26-JUL-2023	120054 Rev F	English • Download
21-APR-2022	120055 Rev E	German • Download
04-APR-2022	120054 Rev E	English • Download
08-MAR-2021	120055 Rev D	German • Download
08-MAR-2021	120054 Rev D	English • Download

Publication Date	Document and Revision number	Language
26-JUL-2023	120056 Rev E	Italian • Download
26-JUL-2023	120056 Rev E	English • Download
21-APR-2022	120056 Rev D	Italian • Download
21-APR-2022	120056 Rev D	English • Download
08-MAR-2021	120056 Rev C	Italian • Download
08-MAR-2021	120056 Rev C	English • Download

Publication Date	Document and Revision number	Language
26-JUL-2023	120055 Rev F	Dutch • Download
26-JUL-2023	120054 Rev F	English • Download
21-APR-2022	120055 Rev E	Dutch • Download
04-APR-2022	120054 Rev E	English • Download
08-MAR-2021	120055 Rev D	Dutch • Download
08-MAR-2021	120054 Rev D	English • Download

Publication Date	Document and Revision number	Language
26-JUL-2023	120056 Rev E	Portuguese • Download
26-JUL-2023	120056 Rev E	English • Download
21-APR-2022	120056 Rev D	Portuguese • Download
21-APR-2022	120056 Rev D	English • Download
08-MAR-2021	120056 Rev C	Portuguese • Download
08-MAR-2021	120056 Rev C	English • Download

Publication Date	Document and Revision number	Language
22-JAN-2024	120057 Rev F	Spanish • Download
22-JAN-2024	120057 Rev F	English • Download
26-JUL-2023	120057 Rev E	Spanish • Download
26-JUL-2023	120057 Rev E	English • Download
21-APR-2022	120057 Rev D	Spanish • Download
21-APR-2022	120057 Rev D	English • Download
08-MAR-2021	120057 Rev C	Spanish • Download
08-MAR-2021	120057 Rev C	English • Download

Publication Date	Document and Revision number	Language
22-JAN-2024	120057 Rev F	Swedish • Download
22-JAN-2024	120057 Rev F	English • Download

Publication Date	Document and Revision number	Language
21-APR-2022	120040 Rev G	Turkish • Download
21-APR-2022	120040 Rev G	English • Download
08-MAR-2021	120040 Rev F	Turkish • Download
08-MAR-2021	120040 Rev F	English • Download

Modi, S., Gibson, T., Vigneswaran, G., Patel, S., Wheater, M., Karydis, I., Gupta, S., Takhar, A., Pearce, N., Ottensmeier, C. and Stedman, B., 2022. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Research, Publish Ahead of Print/li>
Ann Surg Oncol https://doi.org/10.1245/s10434-024-15293-x
Melanomafocus.org. 2023. UK Uveal Melanoma Guidelines. [online] Available at: https://melanomafocus.org/wpcontent/uploads/2022/06/2_UM_Guideline_v7_6.pdf [Accessed 16 March 2023].
Leitlinienprogramm Onkologie - S3 Guidelines Melanoma Germany. https://www.leitlinienprogrammonkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Melanom/Melanom_Version_3/LL_Melanom_Langversion_3.3.pdf [Accessed 16 March 2023]
Meijer, T., Burgmans, M., de Leede, E., de Geus-Oei, L., Boekestijn, B., Handgraaf, H., Hilling, D., Lutjeboer, J., Vuijk, J., Martini, C., van Erkel, A., van der Meer, R., Tijl, F., Speetjens, F., Kapiteijn, E. and Vahrmeijer, A., 2020. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. Annals of Surgical Oncology, 28(2), pp.1130-1141
Karydis, I., Gangi, A., Wheater, M., Choi, J., W1-3ilson, I., Thomas, K., Pearce, N., Takhar, A., Gupta, S., Hardman, D., Sileno, S., Stedman, B., Zager, J. and Ottensmeier, C., 2017. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 117(6), pp.1170-1178.
Brüning, R., Tiede, M., Schneider, M., Wohlmuth, P., Weilert, H., Oldhafer, K. and Stang, A., 2020. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. Radiology Research and Practice, 2020, pp.1-7.
de Leede, E., Burgmans, M., Martini, C., Tijl, F., van Erkel, A., Vuyk, J., Kapiteijn, E., Verhoef, C., van de Velde, C. and Vahrmeijer, A., 2016. Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver. Journal of Visualized Experiments, (113).

Vogel, A., Gupta, S., Zeile, M., v on Haken, R., Brüning, R., Lotz, G., Vahrmeijer, A., Vogl, T. and Wacker , F., 2016. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Advances in Therapy, 33(12), pp.2122-2138.
Artzner, C., Mossakowski, O., H efferman, G., Grosse, U., Hoffmann, R., Forschner, A., Eigentler, T., Syha, R. and Grözinger 4, G., 2019. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging, 19(1).
Chemosat.com. IFU 2022. [online] Available at: [Accessed 1 March 2022]

Karydis, I., Gangi, A., Wheater, M., Choi, J., W1-3ilson, I., Thomas, K., Pearce, N., Takhar, A., Gupta, S., Hardman, D., Sileno, S., Stedman, B., Zager, J. and Ottensmeier, C., 2017. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 117(6), pp.1170-1178.
Brüning, R., Tiede, M., Schneider, M., Wohlmuth, P., Weilert, H., Oldhafer, K. and Stang, A., 2020. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. Radiology Research and Practice, 2020, pp.1-7.
Vogel, A., Gupta, S., Zeile, M., v on Haken, R., Brüning, R., Lotz, G., Vahrmeijer, A., Vogl, T. and Wacker , F., 2016. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Advances in Therapy, 33(12), pp.2122-2138.
Zager, J.S., Orloff, M., Ferrucci, P.F. et al. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15293-x
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
Delcath Systems Inc. Data on file. 2.5 Clinical overview: Melphalan/HDS; hepatic-dominant ocular melanoma. 2022.
Meijer, T., Burgmans, M., de Leede, E., de Geus-Oei, L., Boekestijn, B., Handgraaf, H., Hilling, D., Lutjeboer, J., Vuijk, J., Martini, C., van Erkel, A., van der Meer, R., Tijl, F., Speetjens, F., Kapiteijn, E. and Vahrmeijer, A., 2020. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. Annals of Surgical Oncology, 28(2), pp.1130-1141
Modi, S., Gibson, T., Vigneswaran, G., Patel, S., Wheater, M., Karydis, I., Gupta, S., Takhar, A., Pearce, N., Ottensmeier, C. and Stedman, B., 2022. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Research, Publish Ahead of Print
Artzner, C., Mossakowski, O., H efferman, G., Grosse, U., Hoffmann, R., Forschner, A., Eigentler, T., Syha, R. and Grözinger 4, G., 2019. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging, 19(1).

Melanomafocus.org. 2023. UK Uveal Melanoma Guidelines. [online] Available at: https://melanomafocus.org/wpcontent/uploads/2022/06/2_UM_Guideline_v7_6.pdf [Accessed 16 March 2023].
Leitlinienprogramm Onkologie - S3 Guidelines Melanoma Germany. https://www.leitlinienprogrammonkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Melanom/Melanom_Version_3/LL_Melanom_Langversion_3.3.pdf [Accessed 16 March 2023]
Karydis, I., Gangi, A., Wheater, M., Choi, J., W1-3ilson, I., Thomas, K., Pearce, N., Takhar, A., Gupta, S., Hardman, D., Sileno, S., Stedman, B., Zager, J. and Ottensmeier, C., 2017. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 117(6), pp.1170-1178.
Brüning, R., Tiede, M., Schneider, M., Wohlmuth, P., Weilert, H., Oldhafer, K. and Stang, A., 2020. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. Radiology Research and Practice, 2020, pp.1-7.
Vogel, A., Gupta, S., Zeile, M., v on Haken, R., Brüning, R., Lotz, G., Vahrmeijer, A., Vogl, T. and Wacker , F., 2016. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Advances in Therapy, 33(12), pp.2122-2138.
Artzner, C., Mossakowski, O., H efferman, G., Grosse, U., Hoffmann, R., Forschner, A., Eigentler, T., Syha, R. and Grözinger 4, G., 2019. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging, 19(1).
https://clinicaltrials.gov/ct2/show/NCT02678572?term=FOCUS&cond=Uveal+Melanoma&draw=2&rank=3

Using our website

Our website (“chemosat.com”) uses cookies to improve your experience and to provide tailored information.

What are cookies?

Cookies are text files stored on your computer so that when you visit a website it can remember who you are. Using cookies allows websites to remember your preferences and behaviour which enables websites to improve your experience.

Cookies can be set by the owner of the website or in some cases by third-party services the website owner allows to present or store other information or provide other functionality such as data analytics.

How are they used on this site?

Cookies are used to improve the functionality of our website.

This website uses session cookies. Session cookies are used to deliver the basic functions of a website i.e. to allow pages to remember technical changes or selections you may make between pages. Session cookies are temporary cookies and are generally erased when you close your browser.

We may also use cookies set by third parties for other functionalities such as data analytics and improved targeted advertising.

Managing & Removing Cookies

Should you change your mind in the future you always have the option of removing cookies from your browser. Please the below links depending on your browser: